Skip to main content

Advertisement

SpringerLink
Log in

Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient

  • Liver Transplantation (D Mulligan and R Batra, Section Editors)
  • Published:
Current Transplantation Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Nonalcoholic fatty liver disease (NAFLD) may occur as a de novo or recurrent disease among recipients of liver transplant (LT). We seek to review the currently available information on the diagnosis, implications, and management of NAFLD in the post LT population with a focus on the practical medical management of this disease.

Recent Findings

Recent studies emphasize that NAFLD is the hepatic manifestation of the metabolic syndrome, mediated largely by insulin resistance, with liver recipient factors being the primary determinants of the development of graft steatosis. Post-transplant nonalcoholic steatohepatitis (NASH) may progress to the development of graft fibrosis and cirrhosis. Risk factors such as hypertension, dyslipidemia, hyperglycemia, and excess weight gain should be addressed proactively in the post-transplant period.

Summary

Interventions to prevent or treat NAFLD in the patient who has undergone LT must take into account the specialized needs of the post-transplant care setting, including the management of immunosuppression, and the potential presence of high catabolic needs after surgery. Future research is needed to tailor NAFLD interventions to the post-transplant population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Charlton MR. Improving long-term outcomes after liver transplantation. Clin Liver Dis. 2014;18:717–30. https://doi.org/10.1016/j.cld.2014.05.011.

    Article  PubMed  Google Scholar 

  2. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57. https://doi.org/10.1002/hep.29367.

    Article  PubMed  Google Scholar 

  3. Boppidi H, Daram SR. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome. Postgrad Med. 2008;120:E01–7. https://doi.org/10.3810/pgm.2008.07.1800.

    Article  PubMed  Google Scholar 

  4. Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, et al. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. BMC Gastroenterol. 2018;18:165. https://doi.org/10.1186/s12876-018-0900-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. • Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? J Hepatol. 2018;68:326–34. https://doi.org/10.1016/j.jhep.2017.10.006A paper which outlines the risks of HCC development in persons with NAFLD, and suggests a possible role for surveillance in this increasingly frequent clinical scenario.

    Article  PubMed  Google Scholar 

  6. Kwong A, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, et al. OPTN/SRTR 2018 Annual data report: liver. Am J Transplant. 2020;S1:193–299. https://doi.org/10.1111/ajt.15674.

    Article  Google Scholar 

  7. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664–9. https://doi.org/10.1002/hep.510290347.

    Article  CAS  PubMed  Google Scholar 

  8. Andrade ARCF, Cotrim HP, Bittencourt PL, Almeida CG, Sorte NCAB. Nonalcoholic steatohepatitis in posttransplantation liver: review article. Rev Assoc Med Bras. 2018;64:187–94. https://doi.org/10.1590/1806-9282.64.02.187.

    Article  PubMed  Google Scholar 

  9. Tanaka T, Sugawara Y, Tamura S, Kaneko J, Takazawa Y, Aoki T, et al. Living donor liver transplantation for non-alcoholic steatohepatitis: a single center experience. Hepatol Res. 2014;44:E3–10. https://doi.org/10.1111/hepr.12200.

    Article  PubMed  Google Scholar 

  10. Vallin M, Guillaud O, Boillot O, Hervieu V, Scoazec JY, Dumortier J. Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis. Liver Transpl. 2014;20:1064–71. https://doi.org/10.1002/lt.23936.

    Article  PubMed  Google Scholar 

  11. Galvin Z, Rajakumar R, Chen E, Adeyi O, Selzner M, Grant D, et al. Predictors of de novo nonalcoholic fatty liver disease after liver transplantation and associated fibrosis. Liver Transpl. 2019;25:56–67. https://doi.org/10.1002/lt.25338.

    Article  PubMed  Google Scholar 

  12. Bhati C, Idowu MO, Sanyal AJ, Rivera M, Driscoll C, Stravitz RT, et al. Long-term outcomes in patients undergoing liver transplantation for nonalcoholic steatohepatitis-related cirrhosis. Transplantation. 2017;101:1867–74. https://doi.org/10.1097/TP.0000000000001709.

    Article  PubMed  Google Scholar 

  13. Dureja P, Mellinger J, Agni R, Chang F, Avey G, Lucey M, et al. NAFLD recurrence in liver transplant recipients. Transplantation. 2011;91:684–9. https://doi.org/10.1097/TP.0b013e31820b6b84.

    Article  PubMed  Google Scholar 

  14. Germani G, Laryea M, Rubbia-Brandt L, Egawa H, Burra P, O’Grady J, et al. Management of recurrent and de novo NAFLD/NASH after liver transplantation. Transplantation. 2019;103:57–67. https://doi.org/10.1097/TP.0000000000002485.

    Article  PubMed  Google Scholar 

  15. Marchetti P. New-onset diabetes after transplantation. J Heart Lung Transplant. 2004;23:S194–01. https://doi.org/10.1016/j.healun.2004.03.007.

    Article  PubMed  Google Scholar 

  16. Montero N, Pascual J. Immunosuppression and post-transplant hyperglycemia. Curr Diabetes Rev. 2015;11:144–54. https://doi.org/10.2174/1573399811666150331160846.

    Article  CAS  PubMed  Google Scholar 

  17. Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”. Am J Gastroenterol. 2020;105:613–20. https://doi.org/10.1038/ajg.2009.717.

    Article  Google Scholar 

  18. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010;16:431–9. https://doi.org/10.1002/lt.22004.

    Article  PubMed  Google Scholar 

  19. Kurdi A, Martinet W, De Meyer GRY. mTOR inhibition and cardiovascular diseases: dyslipidemia and atherosclerosis. Transplantation. 2018;102:S44–6. https://doi.org/10.1097/TP.0000000000001693.

    Article  CAS  PubMed  Google Scholar 

  20. Finkenstedt A, Auer C, Glody B, Posch U, Steitzer H, Lanzer G, et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol. 2013;11:1667–72. https://doi.org/10.1016/j.cgh.2013.06.025.

    Article  CAS  PubMed  Google Scholar 

  21. Trunečka P, Míková I, Dlouhá D, Hubáček JA, Honsová E, Kolesár L, et al. Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study. 2018. Dig Liver Dis. 2018;50:490–5. https://doi.org/10.1016/j.dld.2017.12.030.

    Article  CAS  PubMed  Google Scholar 

  22. Miyagawa-Hayashino A, Egawa H, Yorifuji T, Hasegawa M, Haga H, Tsuruyama T, et al. Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation. Liver Transpl. 2009;15:610–8. https://doi.org/10.1002/lt.21686.

    Article  PubMed  Google Scholar 

  23. El Atrache MM, Abouljoud MS, Divine G, Yoshida A, Kim D, Kazimi MM, et al. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome. Clin Transpl. 2012;26:E505–12. https://doi.org/10.1111/ctr.12014.

    Article  Google Scholar 

  24. Boga S, Munoz-Abraham A, Rodriguez-Davalos M, Emre SH, Jain D, Schilsky ML. Host factors are dominant in the development of post-liver transplant non-alcoholic steatohepatitis. 2016. World J Hepatol. 2016;8:659–64. https://doi.org/10.4254/wjh.v8.i15.659.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Alten TA, Negm AA, Voigtländer T, Jaeckel E, Lehner F, Brauner C, et al. Safety and performance of liver biopsies in liver transplant recipients. Clin Transpl. 2014;28:585–9. https://doi.org/10.1111/ctr.12352.

    Article  Google Scholar 

  26. Gu J, Liu S, Du S, Zhang Q, Xiao J, Dong Q, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol. 2019;29:3564–73. https://doi.org/10.1007/s00330-019-06072-4.

    Article  PubMed  Google Scholar 

  27. Dulai P, Sirlin C, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65:1006–16. https://doi.org/10.1016/j.jhep.2016.06.005.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Van Werven JR, Marsman HA, Nederveen AJ, Smits NJ, Kate FJ, Gulik TM, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MRI imaging, and point-resolved 1H-MR spectroscopy. Radiology. 2010;256:159–68. https://doi.org/10.1148/radiol.10091790.

    Article  PubMed  Google Scholar 

  29. Caussy C, Alquiraish MH, Nguyen P, Hernandez C, Cepin S, Fortney LE, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018;67:1348–59. https://doi.org/10.1002/hep.29639.

    Article  CAS  PubMed  Google Scholar 

  30. Crespo G, Castro-Narro G, Garcia-Juarez I, Benítez C, Ruiz P, Sastre L, et al. Usefulness of liver stiffness measurement during acute cellular rejection in liver transplantation. Liver Transpl. 2016;22:298–04. https://doi.org/10.1002/lt.24376.

    Article  PubMed  Google Scholar 

  31. Gitto S, Marra F, De Maria N, Bihl F, Villa E, Andreone P, et al. Nonalcoholic steatohepatitis before and after liver transplantation: keeping up with the times. Expert Rev Gastroenterol Hepatol. 2019;13:173–8. https://doi.org/10.1080/17474124.2019.1551132.

    Article  CAS  PubMed  Google Scholar 

  32. Cotter TG, Charlton M. Nonalcoholic steatohepatitis after liver transplantation. Liver Transpl. 2020;26:141–59. https://doi.org/10.1002/lt.25657.

    Article  PubMed  Google Scholar 

  33. Siddiqui MS, Charlton M. Liver transplantation for alcoholic and nonalcoholic fatty liver disease: pretransplant selection and posttransplant management. Gastroenterology. 2016;150:1849–62. https://doi.org/10.1053/j.gastro.2016.02.077.

    Article  PubMed  Google Scholar 

  34. Khan RS, Newsome PN. Non-alcoholic fatty liver disease and liver transplantation. Metabolism. 2016;65:1208–23. https://doi.org/10.1016/j.metabol.2016.02.013.

    Article  CAS  PubMed  Google Scholar 

  35. Narayanan P, Mara K, Izzy M, Dierkhising R, Heimbach J, Allen A, et al. Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation. Transplantation. 2019;103:e14–21. https://doi.org/10.1097/TP0000000000002317.

    Article  PubMed  Google Scholar 

  36. Aby ES, Lee E, Saggi SS, Viramontes MR, Grotts JF, Agopian VG, et al. Pretransplant sarcopenia in patients with NASH cirrhosis does not impact rehospitalization or mortality. 2018. J Clin Gastroenterol. 2019;53:680–5. https://doi.org/10.1097/MCG0000000000001109.

    Article  CAS  PubMed  Google Scholar 

  37. Carias S, Castellanos AL, Vilchez V, Nair R, Dela Cruz AC, Watkins J, et al. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation. J Gastroenterol Hepatol. 2016;31:628–33. https://doi.org/10.1111/jgh.13166.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Tandon P, Ismond KP, Riess K, Duarte-Rojo A, Al-Judaibi B, Dunn MA, et al. Exercise in cirrhosis: translating evidence and experience into practice. J Hepatol. 2018;69:1164–77. https://doi.org/10.1016/j.jhep.2018.06.017.

    Article  PubMed  Google Scholar 

  39. Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int. 2005;18:461–6. https://doi.org/10.1111/j.1432-2277.2004.00067.x.

    Article  PubMed  Google Scholar 

  40. Anastácio LR, Ferreira LG, Ribeiro HS, Diniz KGD, Lima AS, Correia MITD, et al. Sarcopenia, obesity, and sarcopenic obesity in liver transplantation: a body composition prospective study. Arq Bras Cir Dig. 2019;32:e1434. https://doi.org/10.1590/0102-672020190001e1434.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–9. https://doi.org/10.1002/hep.23276.

    Article  CAS  PubMed  Google Scholar 

  42. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–84. https://doi.org/10.1016/j.jhep.2010.04.008.

    Article  PubMed  Google Scholar 

  43. Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59:138–43. https://doi.org/10.1016/j.jhep.2013.02.012.

    Article  CAS  PubMed  Google Scholar 

  44. Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T, et al. Aerobic vs resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol. 2017;66:142–52. https://doi.org/10.1016/j.jhep.2016.08.023.

    Article  PubMed  Google Scholar 

  45. Krasnoff JB, Vintro AQ, Ascher NL, Bass NM, Paul SM, Dodd MJ, et al. A randomized trial of exercise and dietary counseling after liver transplantation. Am J Transplant. 2006;6:1896–05. https://doi.org/10.1111/j.1600-6143.2006.01391.x.

    Article  CAS  PubMed  Google Scholar 

  46. Osseis M, Lazzati A, Salloum C, Gavara CG, Compagnon P, Feray C, et al. Sleeve gastrectomy after liver transplantation: feasibility and outcomes. ObesSurg. 2018;28:242–8. https://doi.org/10.1007/s11695-017-2843-y.

    Article  Google Scholar 

  47. Elli EF, Gonzalez-Heredia R, Sanchez-Johnsen L, Patel N, Garcia-Roca R, Oberholzer J. Sleeve gastrectomy surgery in obese patients post-organ transplantation. Surg Obes Relat Dis. 2016;12:528–34. https://doi.org/10.1016/j.soard.2015.11.030.

    Article  PubMed  Google Scholar 

  48. Diwan TS, Rice TC, Heimbach JK, Schauer DP. Liver transplantation and bariatric surgery: timing and outcomes. Liver Transpl. 2018;24:1280–7. https://doi.org/10.1002/lt.25303.

    Article  PubMed  Google Scholar 

  49. Heimbach JK, Watt KD, Poterucha JJ, Ziller NF, Cecco SD, Charlton MR, et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant. 2013;13:363–8. https://doi.org/10.1111/j.1600-6143.2012.04318.x.

    Article  CAS  PubMed  Google Scholar 

  50. Tsien C, Garber A, Narayanan A, Shah SN, Barnes D, Eghtesad B, et al. Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation. J Gastroenterol Hepatol. 2014;29:1250–7. https://doi.org/10.1111/jgh.12524.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Di Cosmo S, Lusignani M, Manini M, Accardi R. Prevalence and risk factors of overweight and obesity after liver transplantation: retrospective study at three years after transplantation. Prof Inferm. 2018;71:3–10. https://doi.org/10.7429/pi.2018.711003.

    Article  PubMed  Google Scholar 

  52. Hall KD, Guo J. Obesity energetics: body weight regulation and the effects of diet composition. Gastroenterology. 2017;152:1718–27 e3. https://doi.org/10.1053/j.gastro.2017.01.052.

    Article  PubMed  Google Scholar 

  53. Charlton M, Rinella M, Patel D, McCague K, Heimbach J, Watt K. Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: results of a randomized multicenter study. Transplantation. 2017;01:2873–82. https://doi.org/10.1097/TP.0000000000001913.

    Article  CAS  Google Scholar 

  54. Harvie M, Howell A. Potential benefits and harms of intermittent energy restriction and intermittent fasting amongst obese, overweight and normal weight subjects-a narrative review of human and animal evidence. Behav Sci (Basel). 2017;7:4. https://doi.org/10.3390/bs7010004.

    Article  Google Scholar 

  55. Ard JD, Lewis KH, Rothberg A, Auriemma A, Coburn SL, Cohen SS, et al. Effectiveness of a total meal replacement program (OPTIFAST Program) on weight loss: results from the OPTIWIN study. Obesity (Silver Spring). 2019;27:22–9. https://doi.org/10.1002/oby.22303.

    Article  Google Scholar 

  56. Do A, Kuszewski EJ, Langberg KA, Mehal WZ. Incorporating weight loss medications into hepatology practice for nonalcoholic steatohepatitis. Hepatology. 2019;70:1443–56. https://doi.org/10.1002/hep.30658.

    Article  PubMed  Google Scholar 

  57. Jannah N, Hild J, Gallagher C, Dietz W. Coverage for obesity prevention and treatment services: analysis of Medicaid and state employee health insurance programs. Obesity (Silver Spring). 2018;26:1834–40. https://doi.org/10.1002/oby.22307.

    Article  Google Scholar 

  58. Brown A, Guess N, Dornhorst A, Taheri S, Frost G. Insulin-associated weight gain in obese type 2 diabetes mellitus patients: what can be done? Diabetes Obes Metab. 2017;19:1655–1. https://doi.org/10.1111/dom.13009.

    Article  PubMed  Google Scholar 

  59. Cheang JY, Moyle PM. Glucagon-like peptide-1 (GLP-1)-based therapeutics: current status and future opportunities beyond type 2 diabetes. ChemMedChem. 2018;13:662–71. https://doi.org/10.1002/cmdc.201700781.

    Article  CAS  PubMed  Google Scholar 

  60. •• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–78.e5. https://doi.org/10.1053/j.gastro.2015.04.005A key study in 293 patients with histologically proven NASH who underwent biopsies before and after 1 year of intensive lifestyle intervention. It showed that that with weight loss in the 5%–8% range there can be significant improvement in liver histology.

    Article  PubMed  Google Scholar 

  61. Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2013;59:536–42. https://doi.org/10.1016/j.jhep.2013.04.013.

    Article  PubMed  Google Scholar 

  62. • Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018;68:763–72. https://doi.org/10.1002/hep.29797A review of noninvasive measurement of hepatic steatosis for clinical and research pruposes.

    Article  PubMed  Google Scholar 

  63. • Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19:1242–51. https://doi.org/10.1111/dom.12932A randomized blinded trial of once a week semaglutide demonstrated reduced appetite, reduced calorie intake, and on average 11lb weight loss.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale University School of Medicine, New Haven, CT, USA

    Jennifer Batisti & Wajahat Z. Mehal

Authors
  1. Jennifer Batisti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wajahat Z. Mehal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer Batisti.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Liver Transplantation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Batisti, J., Mehal, W.Z. Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient. Curr Transpl Rep 7, 332–339 (2020). https://doi.org/10.1007/s40472-020-00303-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40472-020-00303-0

Keywords

Search

Navigation